Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

By Georgina V. Long, A. Hauschild, M. Santinami, V. Atkinson, M. Mandalà, V. Chiarion-Sileni, J. Larkin, M. Nyakas, C. Dutriaux, A. Haydon and 13 more. New England Journal of Medicine, 2017

1,282 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/493d7cd420a2e7967d98d77c82b1ad602ad77970

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Flaherty
2. Georgina V. Long

Citations in the corpus

• Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, background): “Moreover, adjuvant therapy with new agents has shown impressive ability to improve clinical outcomes in patients with resected stage III melanoma.(22-24) It is against this background that the AJCC appointed a Melanoma Expert Panel to undertake the task of revising the cutaneous melanoma staging sys”
• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Contrary to the initial EORTC 18071 ipilimumab trial, HR for RFS are robust and consistent across the various subgroups for the PD-1 trial, EORTC 1325 and CheckMate 238, and the dabrafenib/trametinib trial, COMBI-AD [59].”